Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01128270 · ClinicalTrials.gov registry record · Phase 1
Pharmacotoxicology of Trichloroethylene Metabolites
A Phase 1 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01128270: Completed Phase 1 study, sponsored by University of Florida.
NCT01128270 is a Phase 1 study that has completed, run by University of Florida. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01128270, a Phase 1 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a research study to look at how Dichloroacetate (DCA), and investigational drug and chloral hydrate are broken down in the body. The purpose of the study is to better understand how humans metabolize these two common chemicals that are widely present in the environment. The study focuses on how the drug chloral hydrate is broken down and how it effects DCA
Primary Outcome
After 5 days of of therapeutic level Chloral Hydrate, the levels of Dichloroacetate in the plasma were measured.
Interventions
- DRUG Dichloroacetate environmental dose
- DRUG Chloral Hydrate environmental dose
- DRUG Dichloroacetate therapeutic dose
- DRUG Chloral Hydrate therapeutic dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
What the finished NCT01128270 record still lists
NCT01128270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 4 interventions - of which Dichloroacetate environmental dose is the first listed.
NCT01128270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01128270 about?
NCT01128270 is a clinical study titled "Pharmacotoxicology of Trichloroethylene Metabolites". This is a research study to look at how Dichloroacetate (DCA), and investigational drug and chloral hydrate are broken down in the body. The purpose of the study is to better understand how humans metabolize these two common chemicals that are widely present in the environment. The study focuses on ...
What is the current status of trial NCT01128270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01128270?
The interventions under investigation include: Dichloroacetate environmental dose (DRUG), Chloral Hydrate environmental dose (DRUG), Dichloroacetate therapeutic dose (DRUG), Chloral Hydrate therapeutic dose (DRUG).
Who is sponsoring clinical trial NCT01128270?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01128270's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia